Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Prostate Cancer Clinical Trials Consortium
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07592910CT.gov A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy | — | Not Yet Recruiting | — | — | — |
NCT06616155CT.gov Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06844383CT.gov A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate | — | Recruiting | — | — | — |
NCT06592924CT.gov Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | — | Recruiting | — | — | — |
NCT05726292CT.gov A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | — | Recruiting | — | — | — |
NCT06236139CT.gov Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06499870CT.gov Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial | — | Recruiting | — | — | — |
NCT06257693CT.gov Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | — | Recruiting | — | — | — |
NCT06312670CT.gov Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT05733351CT.gov Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | — | Terminated | — | — | — |
Show 21 more trialsShow fewer
NCT05683964CT.gov Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | — | Active Not Recruiting | — | — | — |
NCT04455750CT.gov A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy | — | Active Not Recruiting | — | — | — |
NCT04471974CT.gov ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04446117CT.gov Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC | — | Active Not Recruiting | — | — | — |
NCT03999515CT.gov Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | — | Terminated | — | — | — |
NCT03829930CT.gov Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | — | Terminated | — | — | — |
NCT03246347CT.gov A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02601014CT.gov Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 | — | Completed | — | — | — |
NCT02532114CT.gov Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT02278185CT.gov Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT02491411CT.gov Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | — | Terminated | — | — | — |
NCT02203695CT.gov Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy | — | Completed | — | — | — |
NCT02525068CT.gov A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC | — | Unknown | — | — | — |
NCT02312557CT.gov Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide | — | Active Not Recruiting | — | — | — |
NCT02268175CT.gov Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | — | Completed | — | — | — |
NCT02058706CT.gov LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer | — | Completed | — | — | — |
NCT02023463CT.gov Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02099864CT.gov Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy | — | Completed | — | — | — |
NCT01949337CT.gov Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT01927627CT.gov Enzalutamide in Patients With High-risk Prostate Cancer | — | Completed | — | — | — |
NCT02228265CT.gov Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Enzalutamide (this asset) | Prostate Cancer Clinical Trials Consortium | P3 | B · 63 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Prednisone | Mayo Clinic | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Bicalutamide | OHSU Knight Cancer Institute | P3 | BB |
| Leuporelin | Mayo Clinic | P3 | BB |
| Goserelin | CancerCare Manitoba | P3 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Enzalutamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P4 | BBB · 73 |
| Prostate Carcinoma | — | P4 | BBB · 73 |
| Breast Carcinoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Enzalutamide in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/enzalutamide-prostate-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →